A detailed history of Cinctive Capital Management LP transactions in Repligen Corp stock. As of the latest transaction made, Cinctive Capital Management LP holds 7,514 shares of RGEN stock, worth $1.16 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
7,514
Holding current value
$1.16 Million
% of portfolio
0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$119.79 - $167.35 $900,102 - $1.26 Million
7,514 New
7,514 $1.12 Million
Q4 2023

Feb 14, 2024

SELL
$114.17 - $185.35 $89,166 - $144,758
-781 Reduced 4.2%
17,816 $3.2 Million
Q3 2023

Nov 14, 2023

BUY
$138.78 - $176.51 $436,185 - $554,770
3,143 Added 20.34%
18,597 $2.96 Million
Q2 2023

Aug 14, 2023

BUY
$138.42 - $180.31 $2.14 Million - $2.79 Million
15,454 New
15,454 $2.19 Million
Q3 2022

Nov 14, 2022

BUY
$160.42 - $256.21 $336,882 - $538,041
2,100 New
2,100 $393,000
Q3 2021

Nov 15, 2021

SELL
$194.77 - $324.21 $2.58 Million - $4.29 Million
-13,246 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$165.87 - $220.95 $1.59 Million - $2.11 Million
9,556 Added 258.97%
13,246 $2.64 Million
Q1 2021

May 17, 2021

SELL
$180.37 - $226.26 $2.48 Million - $3.11 Million
-13,767 Reduced 78.86%
3,690 $717,000
Q4 2020

Feb 16, 2021

BUY
$148.08 - $206.57 $1.11 Million - $1.55 Million
7,481 Added 74.99%
17,457 $3.35 Million
Q3 2020

Nov 16, 2020

SELL
$122.51 - $158.27 $1.19 Million - $1.54 Million
-9,729 Reduced 49.37%
9,976 $1.47 Million
Q2 2020

Aug 14, 2020

BUY
$94.33 - $140.48 $1.86 Million - $2.77 Million
19,705 New
19,705 $2.44 Million
Q1 2020

May 15, 2020

SELL
$84.96 - $109.14 $1.58 Million - $2.02 Million
-18,539 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$73.84 - $93.08 $1.37 Million - $1.73 Million
18,539 New
18,539 $1.72 Million

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.59B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Cinctive Capital Management LP Portfolio

Follow Cinctive Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Cinctive Capital Management LP with notifications on news.